LDL receptor gene therapy

Drug Profile

LDL receptor gene therapy

Latest Information Update: 07 Jan 2002

Price : $50

At a glance

  • Originator Immune Response Corporation; Nonindustrial source
  • Class Antihyperlipidaemics; Gene therapies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Hypercholesterolaemia

Most Recent Events

  • 07 Jan 2002 No-Development-Reported for Hypercholesterolaemia in USA (Infusion)
  • 15 Dec 1995 New profile
  • 15 Dec 1995 Investigation in Hypercholesterolaemia in USA (Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top